Subscribe
Be the first with the news that moves the market- Defence Therapeutics (DTC) signed an agreement with Orano Support to develop an advanced cancer-treating radiation substance
- The idea is to combine iDTC’s Accum technology with certain elements like antibodies to help better target and destroy cancer cells
- DTC is responsible for developing the first radiation carrier compound therapy with its existing technology and Orano’s radiochemistry knowledge
- Defence Therapeutics (DTC) is up 4.40 per cent, trading at $3.80 per share as of 11:53 a.m. ET
Defence Therapeutics (DTC) has signed an agreement with nuclear energy group, Orano Support, to develop an advanced cancer-treating radiation substance.
DTC stated the proposed radiation substance will use its intracellular targeting technology to support radiotherapies. Its concept is to combine its Accum technology with certain elements like antibodies to help better target and destroy cancer cells.
The Accum platform has been developed and tested in animals to enhance intranuclear drug delivery on multiple US FDA-approved antibody conjugates or new conjugates under development.
“We have a long-standing knowledge and experience working and developing our Accum platform technology, including in the antibody-conjugate therapeutics field, and we definitely believe that Orano, with its international expertise, represents a strong collaborator for the development of the next generation of radio-immuno-conjugates using Defence’s intracellular targeting technology to increase the efficacy in targeting tumoral cancer cells,” Sebastien Plouffe, President and CEO of DTC, said.
As a part of the agreement, DTC is responsible for developing the first radiation carrier compound therapy based on a specific electron emitter with its existing intracellular technology and Orano’s radiochemistry knowledge.
According to the company, existing antibody drugs for these types of treatments do exist but currently have a lower delivery rate to reach and destroy cancer cells.
Defence Therapeutics (DTC) is up 4.40 per cent, trading at $3.80 per share as of 11:53 a.m. ET.
